Clinical impact of intratumoral HER2 heterogeneity on trastuzumab eficacy

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10123
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Japanese Foundation for Cancer Research
• Principal Investigator: Wakatsuki Takeru 公益財団法人がん研究会, 有明病院 消化器内科, 副医長 (60443876)
• Co-Investigator(Renkei-kenkyūsha): Yamamoto Noriko 公益財団法人がん研究会, がん研究所 病理部, 主任研究員 (10280629) ; Mashima Tetsuo 公益財団法人がん研究会, がん化学療法センター 分子生物治療研究部, 主任研究員 (30311228) ; Mori Seiichi 公益財団法人がん研究会, がんプレシジョン医療研究センター 次世代がん研究シーズ育成プロジェクト, プロジェクトリーダー (10334814) ; Sano Takeshi 公益財団法人がん研究会, 有明病院, 副院長 (30215884)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: HER2 / Gastric cancer / HER2 heterogeneity / Trastuzumab / Biomarker

Outline of Final Research Achievements

Intratumoral HER2 heterogeneity is ofted seen in gastric cancer. We evaluated an association between HER2 heterogeneity and trasutuzumab efficacy. We obtained new findings as follows; 1: When used surgical specimens, patients whose tumor homogeneously overexpressed HER2 protein had substantial benefit from trastuzumab. 2: When used biopsy specimens, similar results were obtained but its impact was modest compared with surgical specimens. 3: patients whose tumor heterogeneously overexpressed HER2 protein had modest benefit regardless types of tumor sample. HER2 heterogeneity in surgical specimens is useful biomarker as a positive predictor for anti-HER2 agents, while HER2 heterogeneity in biopsy specimens should be used as a negative predictor.

Free Research Field

消化器化学療法、トランスレーショナルリサーチ